Der Kaninchen Polyklonal anti-SRPX2 Antikörper (ABIN6991221) detektiert spezifisch SRPX2 in WB, ELISA, IHC (p) und IF.
Dieser Antikörper reagiert spezifisch mit Proben aus Maus, Human und Ratte.
SRPX2 Antibody is affinity chromatography purified via peptide column.
Immunogen
SRPX2 antibody was raised against a 16 amino acid synthetic peptide from near the amino terminus of human SRPX2. The immunogen is located within the first 50 amino acids of SRPX2.
SRPX2
Reaktivität: Maus
WB, IF (cc), IF (p)
Wirt: Kaninchen
Polyclonal
Cy3
Applikationshinweise
SRPX2 antibody can be used for detection of SRPX2 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in rat samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
SRPX2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
SRPX2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
SRPX2 Antibody: Sushi-repeat-containing protein X-linked 2 (SRPX2) is a neural gene functioning in the speech and language center of the human brain, mutations in this gene lead to epilepsy, speech dyspraxia, mental retardation and cognitive disorders. Recently, SRPX2 was found to be a novel mediator of angiogenesis and can act as a ligand for the urokinase-type plasminogen activator, a protein that can facilitate invasive migration of sprouting endothelial cells. SRPX2 is also overexpressed in gastric cancer, leading to increased phosphorylation levels of focal adhesion kinase and enhanced cellular migration and adhesion, suggesting that SRPX2 may be a potential target in the treatment of metastatic cancers.